The bioreactor is expected to allow BrainStorm to optimize its NurOwn production process by using a single clean room for multiple patients, reducing costs and time.
As part of the agreement, the companies using Octane’s Automated Cell & Tissue Engineering System (ACTES) technology will develop bioreactor, which meets commercial and cost-effective standards, to increase BrainStorm’s NurOwn stem cell therapy.
BrainStorm CEO Adrian Harel said, "We are anxious to move ahead with this project, in order to be in a position to provide NurOwn as quickly as possible, and to as many patients as possible, in the near future."
Octane CEO Tim Smith said, "We are confident that our combined knowledge base and commitment to the project will help advance their product significantly closer to clinical use.”
BrainStorm is at present conducting a phase I/II clinical trial at the Hadassah Medical Center in Jerusalem.
The companies will use fund granted by the Canada-Israel Industrial Research and Development Foundation spread for three years.